In a defiant move, AMAG Pharmaceuticals (AMAG) is refusing to voluntarily withdraw its controversial treatment for preventing premature births, despite a request to do so made earlier this month by the Food and Drug Administration. Instead, the drug maker is seeking a hearing to review the rationale given by the regulator for wanting its Makena medication pulled off the market.

The agency explained that a required post-marketing study had failed to verify a clinical benefit and that available evidence does not show Makena is effective for its approved use. A year ago, an FDA advisory panel reached the same conclusion and recommended that the drug — which has been a standard of care across the U.S. since it was approved nine years ago — should be withdrawn.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy